David Vocadlo completed his Ph.D. at the University of British Columbia in 2002. He was a postdoctoral fellow at the University of California at Berkeley in the Department of Chemistry. In 2004 he moved to Simon Fraser University (SFU) where he is now Professor in the Departments of Chemistry and Molecular Biology & Biochemistry, Co-Director of the Center for High-Throughput Chemical Biology and Distinguished University Professor of Chemical Biology. His research focuses on developing chemical biology tools to advance understanding the roles of glycoconjugates in health and disease. Dr. Vocadlo pioneered the creation and preclinical validation of OGA inhibitors for neurodegenerative diseases, a strategy now advanced by several companies into clinic trials. His research has been recognized with various awards including the EWR Steacie Memorial Fellowship, the Horace Isbell Award of the American Chemical Society and appointment as a member of the Royal Society of Canada.
Associated Grants
-
Bidirectional Genome-wide CRISPRi/a Screening Using Ratiometric GCase Substrates to Identify Genetic Modulators of Lysosomal GCase Activity
2026
-
Implementation and Validation of Lysosome-specific Tests of GCase Activity in Cell Lines and Human Peripheral Blood
2023
-
-
Developing an Assay to Identify Glucocerebrosidase-enhancing Chaperones for the Treatment of Parkinson’s Disease
2022